š [408+ Pages Report] According to a market research study published by Coherent Market Insights, the demand analysis of China Ulcerative Colitis Market size & share revenue was valued at around US$ 190.2 Million in 2022 and is estimated to grow about US$ 246.3 Million by 2030, at a CAGR of approximately 3.3% between 2022 and 2030.
Inflammation and ulcers in the digestive tract are symptoms of the inflammatory bowel disease group known as ulcerative colitis. The rectum and colon’s inner lining are both impacted by ulcerative colitis. Depending on the degree of inflammation, symptoms often appear gradually. Drug therapy can alleviate minor symptoms, but surgery is required to address severe ones. If ulcerative colitis lasts for more than 8 years or longer, colon cancer may develop. Increasing healthcare preventative measures also causes a gradual increase in sensitivity to the benefits of therapy. Drugs and cutting-edge therapies also lower the risk of developing colon cancer in preventative healthcare. A perforated colon, a colon that is enlarging quickly, severe bleeding, osteoporosis, an increased risk of blood clots in veins and arteries, and severe dehydration are all potential consequences of ulcerative colitis. Although the precise aetiology of ulcerative colitis is unknown, hereditary factors, environmental changes, or a compromised immune system are some of the potential causes. Simple healthy practises like eating small meals often, drinking enough of water throughout the day, avoiding greasy foods, and limiting the consumption of high-fiber foods can help to prevent ulcerative colitis.
Request FREE Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/4862
Our Sample Report Consists of the Following:
- Introduction, Overview, and in-depth industry analysis are all included in the 2021 updated report.
- The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
- About 408+ Pages Research Report (Including Recent Research)
- Provide detailed chapter-by-chapter guidance on Request
- Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2021
- Includes Tables and figures have been updated
- The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
- Coherent Market InsightsĀ research methodology
The COVID-19 epidemic and lockdown in several nations throughout the world have had an effect on the financial health of companies in all industries, including the private healthcare sector. Due primarily to rigorous lockdown in many areas, the COVID-19 pandemic has affected the whole supply chain of the healthcare business. The COVID-19 pandemic has impacted the economies of several countries throughout the world in three primary ways: by directly altering supply and demand; by causing disruptions in the routes of distribution; and by having a financial impact on businesses and financial markets. Healthcare product distribution and transportation are issues in a number of nations, including Singapore, Thailand, and Indonesia. The COVID-19 pandemic has had a significant negative influence on the care of inflammatory bowel disease (IBD), significantly restricting hospitalizations and delaying diagnostic tests.
Ā
Therefore, throughout the projected period, the influence of the Coronavirus (COVID-19) pandemic is anticipated to restrain the growth of the China ulcerative colitis market. For instance, the management of patients with numerous chronic conditions, such as ulcerative colitis and inflammatory bowel disease, is changing as a result of the coronavirus (COVID-19) pandemic, according to a study published in April 2020 in the Lancet (IBD). Additionally, normal endoscopy in particular was momentarily banned from hospitals, but emergency endoscopy is now permitted in a number of those nations where the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has spread. There are presently no particular endoscopic advice for IBD patients in the midst of the epidemic that are supported by concrete data. IBD patients were advised to adhere to the general public health measures recommended by the World Health Organization (WHO), especially those involving systemic corticosteroids, thiopurine, and biologics because they are thought to be moderate-to-high risk individuals who are vulnerable to COVID-19 and its complications.
Ā
Market participants are engaged in research and development activities to provide novel ulcerative colitis treatments. Over the course of the projected period, this is anticipated to fuel market expansion for ulcerative colitis in China.
Download PDF BrochureĀ with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4862
Market participants are engaged in research and development efforts for the creation of a novel ulcerative colitis therapy. Over the projected period, this is anticipated to fuel the market for ulcerative colitis in China. As an illustration, Connect Biopharma, a biopharmaceutical firm with headquarters in China, finished subject enrollment in the phase II clinical trial of its oral treatment, CBP-307, in people with moderate-to-severe ulcerative colitis in 2021. (UC). A tiny chemical that modulates the sphingosine-1-phosphate 1 receptor is called CBP-307 (S1P1).
Ā
Additionally, SHR0302, an experimental selective Janus kinase type 1 (JAK1) inhibitor, showed promise in a phase II clinical trial that assessed its safety and effectiveness for the treatment of moderate-to-severe ulcerative colitis in 2021. The corporate headquarters of this biopharmaceutical firm are located in China. Trials are now taking place in the US, China, and other nations. Phase III clinical trials were supposed to begin in 2021, according to the company’s plans.
Competitive Landscape
Major companies with operations in the China ulcerative colitis market include HUTCHMED, AbbVie Inc., Theravance Biopharma, Celltrion Healthcare, EA Pharma Co., Ltd. Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Salix Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline Plc., InDex Pharmaceuticals Holding AB, Eli Lilly and Company, ZERIA Pharmaceutical Co., Ltd., AstraZeneca, BRISTOL-MYERS SQUIBB, Pfizer Inc.,Ā F. Hoffmann-La Roche AG, and Amgen Inc.
Reasons to buy thisĀ China ulcerative colitisĀ Market Report
ā It attempts an analysis of the competing scenario.
ā The current and exceptional product revenue market.
ā An in-depth data on the regional investigation and competitive landscape structure.
ā It benefits in creating an awareness of the important key product segments.
ā The marketing strategies, opportunities, and development factors are explained.
ā China ulcerative colitis market size estimation and recent advancements in the industry are explained.
Buy This Complete Business Report @Ā https://www.coherentmarketinsights.com/insight/buy-now/4862
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Therapy
- Market Snippet, By Dosage Form
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Mergers and Acquisitions
- Market Dynamics
- China Ulcerative Colitis Market – Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Research and Development
- Government Initiatives
- China Ulcerative Colitis Market, By Drug Therapy, 2017-2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- 5-Aminosalicylates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Mesalazine
- Balsalazide
- Olsazaline
- Others
- Monoclonal Anibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Vedolizumab
- Adalimumab
- Infliximab
- Golimumab
- Ustekimab
- Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Balsalazide
- Prednisone
- Beclomethasone
- Deflazacort
- Others
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Zeposia (ozanimod)
- Etrasimod
- Others
- Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Introduction
- China Ulcerative Colitis Market, By Dosage Form, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Introduction
- China Ulcerative Colitis Market, By Distribution Channel, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Introduction
- Competitive Landscape
- Company Profiles
- AbbVie Inc.*
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Celltrion Healthcare Co., Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Eli Lilly and Company
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca Plc
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Amgen, Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Salix Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Zeria Pharmaceutical Co., Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- InDex Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Boehringer Ingelheim
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- EA Pharma Co., Ltd.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Theravance Biopharma
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- HUTCHMED
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AbbVie Inc.*
- Analyst Views
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email:Ā sales@coherentmarketinsights.com